RegulatoryCompany release

BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M

BeyondSpring, Inc. · Fri 13 Nov 2026

The US regulator's designation covers advanced non-squamous NSCLC after anti-PD-(L)1 and platinum chemotherapy, but the company's third-quarter cash position underlines its continuing need for financing.

BeyondSpring has said the US Food and Drug Administration granted Fast Track designation to plinabulin in combination with docetaxel. The target population is adults with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations, whose disease has progressed after anti-PD-(L)1 therapy and platinum-based chemotherapy. The company announced the news on 13 November 2026 alongside its third-quarter results.

As general context, Fast Track is an FDA programme intended to speed development and review of medicines for serious conditions with unmet need. It allows more frequent contact with the agency and, where criteria are met, rolling submission of an application.

The company also reported that it completed the sale of its Bulin-holding subsidiary to Biolin on 30 September. Under the arrangement, Biolin is funding roughly half of enrolment in DUBLIN-4, a Phase 3 trial planned to include 442 patients, with that portion taking place in China.

Financially, BeyondSpring reported cash of $0.6 million at the end of the quarter and a third-quarter net loss of $2.1 million. The company said it is still pursuing financing.

What it means for your team

  • Fast Track status may support closer FDA interaction on the plinabulin-docetaxel development plan, though it does not signal approval or guarantee a faster outcome.
  • The target setting, post-anti-PD-(L)1 and post-platinum non-squamous NSCLC without actionable alterations, is a population where docetaxel is a relevant comparator for regulators and payers to watch.
  • Teams tracking DUBLIN-4 should note that China enrolment is partly funded by Biolin, and that BeyondSpring's very low cash balance raises questions about funding for the rest of the programme.

Company's press release: BeyondSpring, Inc. ↗

Article written by VigiEye from the official source (BeyondSpring, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →